Overview

Preoperative Olaparib Endometrial Carcinoma Study (POLEN)

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to identify, in human tumour samples, biomarker changes associated to short exposure to AZD2281 as potential predictors of activity in Endometrial Carcinoma (EC). This is an exploratory study with a biological primary endpoint. Clinical efficacy or safety are not a primary objective of the study.
Details
Lead Sponsor:
MedSIR
Collaborators:
AstraZeneca
Experior
Treatments:
Olaparib